viewSynairgen PLC

Synairgen: Richard Marsden presents updates on all three Covid-19 treatment trials

Synairgen PLC's (LON:SNG) Richard Marsden joins Proactive London's Katie Pilbeam to discuss three news updates so far this year. 

Begining with the first patient dosed with its inhaled formulation of interferon beta-1a as part of its global phase III trial in people hospitalised coronavirus (COVID-19).

Secondly, they have put their last patient into their home trial, which means patients don't have to leave their homes at all, ideal for the current lockdown circumstances, all visits are conducted on a zoom call. 

And finally, it's inhaled interferon beta-1a respiratory treatment has been included in a US government-sponsored coronavirus (COVID-19) clinical trial.

Quick facts: Synairgen PLC

Price: 167.3999 GBX

Market: AIM
Market Cap: £334.66 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...


Market Report: Pound gets boost as phase II of vaccine roll out begins after...

The Market Report with Katie Pilbeam. FTSE 100 jumped higher as the UK widened its vaccinating programme after it hit its target of offering the first dose to 15mln priority people by mid-February. London’s leading index jumped 78 points to 6,668 in early trading. In total, more than 15...

1 week, 2 days ago

2 min read